MacroGenics, Inc. (MGNX): Price and Financial Metrics


MacroGenics, Inc. (MGNX): $30.95

0.65 (+2.15%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MGNX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 496

in industry

MGNX POWR Grades


  • MGNX scores best on the Value dimension, with a Value rank ahead of 73.28% of US stocks.
  • MGNX's strongest trending metric is Momentum; it's been moving down over the last 29.7142857142857 weeks.
  • MGNX's current lowest rank is in the Momentum metric (where it is better than 11.47% of US stocks).

MGNX Stock Summary

  • Of note is the ratio of Macrogenics Inc's sales and general administrative expense to its total operating expenses; just 8.69% of US stocks have a lower such ratio.
  • MGNX's price/sales ratio is 16.83; that's higher than the P/S ratio of 88.99% of US stocks.
  • Revenue growth over the past 12 months for Macrogenics Inc comes in at 58.46%, a number that bests 90.33% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Macrogenics Inc, a group of peers worth examining would be SPRO, STRO, CERC, ALKS, and IDYA.
  • MGNX's SEC filings can be seen here. And to visit Macrogenics Inc's official web site, go to www.macrogenics.com.

MGNX Price Target

For more insight on analysts targets of MGNX, see our MGNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $34.50 Average Broker Recommendation 1.42 (Moderate Buy)

MGNX Stock Price Chart Interactive Chart >

Price chart for MGNX

MGNX Price/Volume Stats

Current price $30.95 52-week high $36.48
Prev. close $30.30 52-week low $18.16
Day low $29.90 Volume 379,063
Day high $31.31 Avg. volume 763,763
50-day MA $31.53 Dividend yield N/A
200-day MA $25.73 Market Cap 1.86B

MacroGenics, Inc. (MGNX) Company Bio


Macrogenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. The company was founded in 2000 and is based in Rockville, Maryland.


MGNX Latest News Stream


Event/Time News Detail
Loading, please wait...

MGNX Latest Social Stream


Loading social stream, please wait...

View Full MGNX Social Stream

Latest MGNX News From Around the Web

Below are the latest news stories about Macrogenics Inc that investors may wish to consider to help them evaluate MGNX as an investment opportunity.

Here's Why MacroGenics, Inc.'s (NASDAQ:MGNX) CEO Might See A Pay Rise Soon

The decent performance at MacroGenics, Inc. ( NASDAQ:MGNX ) recently will please most shareholders as they go into the...

Yahoo | May 7, 2021

MacroGenics, Inc. (MGNX) CEO Scott Koenig on Q1 2021 Results - Earnings Call Transcript

MacroGenics, Inc. (MGNX) Q1 2021 Earnings Conference Call April 29, 2021 16:30 ET Company Participants Anna Krassowska - Investor Relations Scott Koenig - President & Chief Executive Officer Jim Karrels - Senior Vice President & Chief Financial Officer Conference Call Participants Jonathan Chang - SVB Leerink Peter Lawson - Barclays...

SA Transcripts on Seeking Alpha | April 30, 2021

MacroGenics (MGNX) Q1 2021 Earnings Call Transcript

Good afternoon, we will begin the MacroGenics 2021 first-quarter corporate progress and financial results conference call in just a moment. At this point, I will turn the call over to Jim Karrels, senior vice president, chief financial officer of MacroGenics. Good afternoon and welcome to MacroGenics'ss conference call to discuss our first-quarter 2021 financial and operational results.

Yahoo | April 30, 2021

The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 28) Axonics, Inc. (NASDAQ: AXNX ) Boston Scientific Corporation (NYSE: BSX ) (reacted to first-quarter results) Celcuity Inc. (NASDAQ: CELC ) Celldex Therapeutics, Inc. (NASDAQ: CLDX) Galectin Therapeutics Inc. (NASDAQ: GALT ) Horizon Therapeutics Public Limited Company (NASDAQ: HZNP ) Insulet Corporation (NASDAQ: PODD ) Integra LifeSciences Holdings Corporation (NASDAQ: IART ) (announced first-quarter results) Lantheus Holdings, Inc. (NASDAQ: LNTH ) MacroGenics, Inc. (NASDAQ: MGNX ) NuVasive, Inc. (NASDAQ: NUVA) PRA Health Sciences, Inc. (NASDAQ: PRAH ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Verastem, Inc. (NASDAQ: VSTM ) Down In The Dumps (Bi...

Benzinga | April 29, 2021

Is MGNX Stock A Buy or Sell?

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 900 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile […]

Yahoo | April 24, 2021

Read More 'MGNX' Stories Here

MGNX Price Returns

1-mo -2.76%
3-mo 57.75%
6-mo 42.43%
1-year 18.58%
3-year 42.30%
5-year 45.17%
YTD 35.39%
2020 110.11%
2019 -14.33%
2018 -33.16%
2017 -7.05%
2016 -34.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8339 seconds.